ERS Genomics and genOway Enter CRISPR/Cas9 Agreement

Product News

Published: June 18, 2021

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "ERS Genomics and genOway Enter CRISPR/Cas9 Agreement"

First Name*

Last Name*

Email Address*

Country*

Company Type*

Job Function*

Would you like to receive further email communication from Technology Networks?

Listen with

Speechify

0:00

Thank you. Listen to this article using the player above. ✖

Read time:

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier have announced a non-exclusive license agreement granting genOway past and future access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

“CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionized many research areas. At ERS, we are committed to make this technology broadly available. We are very pleased to support genOway’s development with this license agreement,” said Eric Rhodes, CEO of ERS Genomics.

“This license from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering,” said Alexandre Fraichard, CEO of genOway. “This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications.”